The aim of the project is to characterize tumor's environment combined with molecular profiling and identification of mechanisms for treatment resistance in metastatic melanoma. Mass cytometry, multicolor flow cytometry, and Nanostring technology will be applied to identify biomarkers of importance. An ex vivo assay to screen patients own tumor tissue for treatment responses will be established and optimized to be applicable for immune therapy. Data obtained from the biomarker studies will be linked to the ex vivo studies of treatment response. The ultimate goal for this project is to predict the clinical outcome and to design effective treatment for patients with metastatic melanoma.